Market research
ERIS.NSE Eris Lifesciences Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 153B
- P/E ratio
- 23.53
- Analyst target
- 1611.7
- Dividend yield
- 0.0%
- Beta
- -0.03
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE406M01024
- Market cap
- 153B
- P/E ratio
- 23.53
- Analyst target
- 1611.7
- Dividend yield
- 0.0%
- Beta
- -0.03
About
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, GLP-1, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram monitoring, continuous glucose monitoring system, sleep device, antenatal care, and early neuropathy screening solutions, as well as polycystic ovary syndrome screening, diagnosis, and management. The company offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Research context
Eris Lifesciences Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ERIS.NSE discussion.
5 years, 6 months ago
Eris Lifesciences Limited is currently in a long term uptrend where the price is trading 24.3% above its 200 day moving average.
From a valuation standpoint, the stock is 44.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Eris Lifesciences Limited's total revenue rose by 14.5% to $3B since the same quarter in the previous year.
Its net income has increased by 42.0% to $902M since the same quarter in the previous year.
Based on the above factors, Eris Lifesciences Limited gets an overall score of 3/5.